Bio-Thera Solutions (SHA:688177) received drug registration certificates from China's National Medical Products Administration for ustekinumab injection, according to a Friday disclosure on the Shanghai bourse.
The certificates include ustekinumab injection and ustekinumab injection in intravenous infusion form, trading as Aisali and Xisali, respectively.
The Chinese drugmaker's shares slipped 1% during the afternoon trade.